Vinge has advised the shareholders of INIM Pharma in connection with the sale of the company to Vicore Pharma Holding, which is listed on First North.
INIM Pharma develops a new local treatment of severe and unusual forms of lung disease such as idiopathic lung fibrosis.
The acquisition is performed as an issue in kind corresponding to a dilution of 35.8 per cent. HealthCap VII LP owns 85 per cent of INIM and following the acquisition HealthCap VII LP will hold approximately 30.4 per cent of the shares in Vicore Pharma Holding.
The transaction is subject to customary closing conditions.
Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg, Jesper Schönbeck, Rikard Lindahl and Malin Malm Waerme.